used CD24/Siglec-10 blocking peptide (CSBP), which blocks the interaction between CD24/Siglec-10 and PD-1/PD-L1, to enhance macrophage-mediated phagocytosis of tumor cells and activate CD8 T cells (39). The gene discussed is CD8A; the disease is neoplasm.